Translational Herbal Pharmacology

Abstract

Translational herbal pharmacology occupies a specific role in the evidence-maturation pipeline for Ayurvedic medicine. Much of the clinical-trial literature evaluates whole-formulation interventions against clinical endpoints, which is appropriate for establishing clinical value but leaves important mechanistic and pharmacokinetic questions under-characterised. Rigorous pharmacological characterisation - bioavailability profiling, herb-drug interaction mapping, formulation standardisation, and target identification - is the infrastructural work that turns clinically-observed effects into reproducible therapeutic agents. We consolidated 72 peer-reviewed pharmacological studies published between 2014 and 2024 evaluating translational-pharmacology dimensions of Ayurvedic herbal agents. Studies were grouped into five frames: HP1 (pharmacokinetic characterisation of classical herbs), HP2 (herb-drug interaction profiling), HP3 (bioavailability enhancement), HP4 (dose-response and standardisation), and HP5 (pharmacodynamic target identification). Each frame was scored on the Translational Herbal Pharmacology Index (THPI), a weighted composite across pharmacokinetic characterisation, mechanistic specificity, formulation standardisation, safety and interaction profiling, and clinical translation. Bioavailability enhancement (HP3) and pharmacodynamic target identification (HP5) scored highest at THPI 0.818 and 0.792. Our reading is that translational pharmacology for Ayurvedic herbs has matured substantially at the bioavailability and target-identification levels, but that herb-drug interaction profiling remains the most clinically-consequential under-addressed area.